Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-05-14

Development of mineral bone substitute injectable by percutaneous a pproach and the minimally invasive catheterization technique

Obiettivo



The elaboration of synthetic material compatible with the bones and tissues of the human body has contributed to the development of new therapeutic methodologies to treat the bone lesions. The PMMA (Polymethylmethracrylite) cement has been used for many years as a filling material for joint implants and more recently for vertebroplasties. Despite its good adhesion and mechanical properties, this acrylic cement presents some drawbacks like side effects and the necrosis of the surrounding tissues resulting from the exothermic reaction developed during the application. Today the tendency is towards the development of bioresorbable and osteoconductor bone substitutes like HAP (hydroxyapatite) which over comes these problems and optimises the bone in growth in the lesion area. Up to now, HAP had been used mainly as a coating material for implants. It has been recently introduced in orthopaedics to treat bone lesions and consolidate bone fractures (pseudarthrosis) in situ.

The product available to the practitioner is a calcium phosphate powder which in presence of water constitutes a paste which will harden and become an HAP in situ. Up to now the consistency of the material has limited its application to the hand packing of lesion in open surgical sites. The objective of the project is to develop a mineral bone substitute inject able by percutaneous approach and capable to fill voids, hollows and areas deficient of bone tissue even in the most distal or less directly reachable places. The new developments will allow the injection through long (40 cm) and narrow (2 mm) catheters. More, the new bone substitute will be inject able in biologic liquid without delitment. A minimal invasive catheterisation technique will be developed to reach the metaphysis and epiphysis lesions or tumour in the long bones from a safe entry point in the diaphysis cortical to avoid open site surgery and direct penetration of the articulation joint.

This new operation technique is expected to reduce very significantly (about 70 %) the medical costs for the foreseen treatments, improve the patient comfort (from a 3 weeks hospital journey to 3 days) and reduce mortality. The SME partners gather the necessary competences to manufacture both the bone substitute and the catheterisation equipment. Starting from the existing technologies, the RTD performers will develop the inject able product and the catheterisation technique. The biomaterial and catheterisation equipment will be developed and tested in vitro on anatomic pieces. The final bone substitute formulation and equipment prototypes will then be validated in vivo on rabbits and sheep. At the end of the project the clinical validation of the new technology on the human will start.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CRS - Cooperative research contracts

Coordinatore

TEKNIMED S.A.
Contributo UE
Nessun dato
Indirizzo
8,Rue du Corps Franc-Pommiès 8
65502 VIC EN BIGORRE
Francia

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (4)

Il mio fascicolo 0 0